butenafine


Also found in: Wikipedia.

butenafine

 [bu-ten´ah-fēn]
a topical antifungal agent used as the hydrochloride salt in the treatment of athlete's foot, jock itch, and ringworm.

butenafine

(byoo-ten-a-feen) ,

Lotrimin Ultra

(trade name),

Mentax

(trade name)

Classification

Therapeutic: antifungals
Pregnancy Category: B

Indications

Treatment of a variety of cutaneous fungal infections, including tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor.

Action

Affects the synthesis of the fungal cell wall.

Therapeutic effects

Decrease in symptoms of fungal infection.

Pharmacokinetics

Absorption: Absorption through intact skin is minimal.
Distribution: Distribution after topical administration is primarily local.
Metabolism and Excretion: Hepatic via hydroxylation.
Half-life: 35 hr.

Time/action profile

ROUTEONSETPEAKDURATION
Topunknownup to 4 wkunknown

Contraindications/Precautions

Contraindicated in: Hypersensitivity to active ingredients, additives, preservatives, or bases; Some products contain alcohol or bisulfites and should be avoided in patients with known intolerance.
Use Cautiously in: Nail and scalp infections (may require additional systemic therapy); Obstetric / Lactation: Safety not established.

Adverse Reactions/Side Effects

Local

  • burning
  • itching
  • local hypersensitivity reactions
  • redness
  • stinging

Interactions

Drug-Drug interaction

None significant.

Route/Dosage

Topical (Adults and Children > 12 yr) Apply once daily for 2 wk for patients with tinea corporis, tinea cruris, or tinea versicolor. Apply once daily for 4 wk or twice daily for 7 days for patients with tinea pedis.

Availability

Cream: 1%Rx, OTC

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)

Implementation

  • Consult physician or other health care professional for proper cleansing technique before applying medication.
  • Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by physician or other health care professional.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes or vaginal area.
  • Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Early relief of symptoms may be seen in 2–3 days. For tinea cruris, tinea corporis, and tinea versicolor, 2 wk are needed, and for tinea pedis, therapeutic response may take 4 wk. Recurrent fungal infections may be a sign of systemic illness.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and.
  • Resolution of infection.

butenafine

/bu·ten·a·fine/ (bu-ten´ah-fēn) a topical antifungal used as the hydrochloride salt in the treatment of tinea pedis, tinea corporis, and tinea cruris.

butenafine

[bu-ten′ah-fēn]
a topical antifungal agent used as the hydrochloride salt in the treatment of athlete's foot, jock itch, and ringworm.
References in periodicals archive ?
21 Terbinafine was purchased from US Pharmacopeia (Washington, DC, USA) and was 99% pure, whereas butenafine was purchased from Toronto Research Chemicals and also was 99% pure.
3% Terbinafine 38% 59% 70% TABLE 3 Agents Available for the Treatment of Tinea Pedis Agent Formulation(s) Mycological Cure Naftifine 2% Cream, gel Once a day x 2 weeks Luliconazole 1% Cream Once a day x 2 weeks Terbinafine 1% Cream, gel, spray Once a day x 1-4 weeks (gel) Twice a day x 1-4 weeks (cream, spray) Butenafine 1% Cream Once a day x 4 weeks Oxiconazole 1% Cream, lotion Once/twice a day x 4 weeks Naftifine 1% Cream, gel Once a day x 4 weeks (cream) Twice a day x 4 weeks (gel) Econazole 1% Cream, foam Once a day x 4 weeks Tolnaftate 1 % Cream, gel, Twice a day x 2-6 weeks powder, spray Sertaconazole Cream Twice a day x 4 weeks nitrate 2% Ciclopirox 0.
In a recent Cochrane review, topical allylamines, azoles, butenafine, ciclopirox olamine, tolciclate, and tolnaftate were all found to be effective.
It contains a biologically active agent selected from the group consisting of terbinafine, naftifine, amorolfine, butenafine, derivatives thereof, salts thereof, or combinations thereof; a delivery vehicle comprising a non-polymeric crystallization inhibitor that is capable of delaying crystallization of the biologically active agent, and a film-former; a volatile solvent in an amount selected to create a subsaturated solution of said biologically active agent; and water.
Background and Objective: N-(1-naphthylmethyl)amine is an important intermediate in the synthesis of biologically active compounds, including allylamine fungicides, such as naftifine, terbinafine, and butenafine.
Isolated skin lesions may be treated effectively with topical griseofulvin, tolnaftate, or butenafine creams applied daily for 7 to 10 days.
In a randomized double-blind trial comparing newer and older therapies, 80 patients with tinea cruris or tinea corporis were placed on once-daily 1% butenafine for 2 weeks or 1% clotrimazole b.
The mycologic cure rate at 2 weeks was 62% with butenafine and 18% with clotrimazole.
The 27% clinical cure rate at 1 week with butenafine was ninefold greater than clotrimazole's 3%.
Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream.
Evaluation of in vitro activity of ciclopiroxolamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.
The increase in brand research and development expenses is primarily due to studies associated with nebivolol and butenafine.